(SPNC) AngioScore Launches New 200 mm Length AngioSculpt® Scoring Balloon Catheters

Longer Balloons Used for the Treatment of Peripheral Artery Disease (PAD) Above-The-Knee (ATK); Incorporates Novel Scoring Element

COLORADO SPRINGS, Colo., July 9, 2014  — The Spectranetics Corporation (Nasdaq:SPNC) today announced that its wholly-owned subsidiary, AngioScore, Inc., developer of novel angioplasty catheters for use in the treatment of cardiovascular disease, launched its new 200 mm length AngioSculpt^® PTA Scoring Balloon Catheters for the treatment of Peripheral Artery Disease (PAD) above-the-knee (ATK).

The new AngioSculpt catheters received U.S. Food and Drug Administration (FDA) 510(k) clearance to be marketed for the dilatation of lesions in the iliac, femoral, iliofemoral, popliteal, infra-popliteal, and renal arteries, and to treat obstructive lesions of native or synthetic arteriovenous dialysis fistulae. They are not approved for use in the coronary or neuro-vasculature.

The catheters incorporate 200 mm balloons in diameters of 4.0, 5.0 and 6.0 mm with a novel scoring element specifically designed for these longer balloons. The devices are expected to be particularly useful in treating the typical complex and long lesions found above-the-knee.

“These new longer scoring balloons extend the capability of the AngioSculpt in treating the most challenging femoro-popliteal lesions safely and efficiently and will be a very important addition to the armamentarium of physicians treating complex endovascular disease,” said Nelson L. Bernardo, MD, medical director of the Peripheral Vascular Laboratory, MedStar Heart Institute, MedStar Washington Hospital Center.

The AngioSculpt balloon catheter was developed by AngioScore, Inc., which was acquired June 30, 2014, by The Spectranetics Corporation. Scott Drake, President and CEO of Spectranetics states that, “We are proud to introduce a viable new product to treat PAD so quickly following the joining of our two companies. At Spectranetics, we focus on solutions for the sickest and trickiest patient population. Now, united with AngioScore, we continue our commitment to provide solutions to cross, prep and treat the most complex morphologies associated with coronary and peripheral diseases.”

Thomas R. Trotter, president of Spectranetics’ AngioScore subsidiary, added, “The treatment of PAD is a rapidly growing segment of the interventional cardiovascular market. Worldwide, over 1 million percutaneous peripheral endovascular procedures are performed annually, and the PAD market continues to demonstrate significant growth due to improved diagnosis and the increasing prevalence of important risk factors such as adult onset diabetes mellitus. We believe that the AngioSculpt line of scoring balloon catheters is particularly useful in treating this very challenging and serious disease.”

About Spectranetics

Spectranetics develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company’s products are sold in over 65 countries and are used to treat arterial blockages in the heart and legs and in the removal of pacemaker and defibrillator leads.

The Company’s Vascular Intervention (VI) products include a range of laser catheters for ablation of blockages in arteries above and below the knee as well as AngioSculpt^® scoring balloon used in both peripheral and coronary procedures. The Company also markets support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions. The Company markets aspiration and cardiac laser catheters to treat blockages in the heart.

The Lead Management (LM) product line includes excimer laser sheaths, mechanical sheaths and accessories for the removal of pacemaker and defibrillator cardiac leads.

For more information, visit http://www.spectranetics.com

About AngioScore

AngioScore, Inc., a Spectranetics company, was acquired in June 2014 by The Spectranetics Corporation in Colorado Springs, Colo. Spectranetics is a leading maker of single-use medical devices used in minimally invasive cardiovascular procedures.

AngioScore Inc. designs, develops, manufactures and markets scoring balloon catheters to treat cardiovascular and peripheral artery diseases. The company was founded in 2003 and is based in Fremont, Calif.

For more information, visit http://www.angioscore.com

About AngioSculpt Scoring Balloon Catheters

AngioSculpt Scoring Balloon Catheters represent the next generation in angioplasty balloon catheters to treat both coronary and peripheral artery disease. Their innovative nitinol scoring elements provide unique circumferential scoring of plaque, leading to precise and predictable luminal enlargement across a wide range of lesion types while minimizing “geographic miss” through their unique anti-slippage properties. AngioSculpt balloon catheters combine the versatility and effectiveness of a new technology with the simplicity and deliverability of traditional high-performance balloon catheters.

AngioSculpt devices have been used in over 350,000 procedures worldwide, achieving an outstanding performance record in the treatment of both coronary and peripheral artery disease.

CONTACT: COMPANY CONTACT
         The Spectranetics Corporation
         Guy Childs, Chief Financial Officer
         (719) 633-8333

         INVESTOR CONTACT
         Westwicke Partners
         Lynn Pieper
         (415) 202-5678
         lynn.pieper@westwicke.com